Outlook Therapeutics, Inc. (OTLK) insider buying and selling

NASDAQ: OTLK · Source: SEC Form 4 filings · Latest trade reported

In the last 90 days at Outlook Therapeutics, Inc. (OTLK), 1 insider made 1 open-market purchase worth $2.5M and there were no open-market sales, as reported on SEC Form 4. Over the last 12 months, 5 insiders bought $7.9M of the stock, led by Ghiath M. Sukhtian (Director), who bought $5.0M on May 28, 2026.

Insider buys, 90 days
1
$2.5M · 1 insider
Insider sales, 90 days
0
$0 · 0 insiders
Insider buys, 12 months
8
$7.9M · 5 insiders
Insider sales, 12 months
0
$0 · 0 insiders

This is the public summary. Create a free account to see OTLK’s AI Signal, the price chart with every insider trade plotted, and each insider’s track record.

Unlock OTLK

Recent open-market insider trades

Trades by the same insider within a week are shown as one line.

Open-market insider trades at Outlook Therapeutics, Inc.
DateInsiderTypeSharesPriceValue
Ghiath M. Sukhtian
Director
Open market purchase2,525,252$0.99$2.5M
Faisal Ghiath Sukhtian
Director
Open market purchase95,398$1.05$100K
Yezan Munther Haddadin
Director
Open market purchase
2 trades
63,000avg. $0.62$39K
Ghiath M. Sukhtian
Director
Open market purchase8,539,709$0.59$5.0M
Faisal Ghiath Sukhtian
Director
Open market purchase122,174$0.41$50K
KURT J HILZINGER
Director
Open market purchase400,000$0.44$177K
RANDY H THURMAN
Director
Open market purchase5,000$0.43$2K

What the OTLK insider trades really mean

The table above is the public summary. With an Insider Intel account you get the analysis behind it, for Outlook Therapeutics, Inc. and every other stock we track:

The AI Signal weighs:Insider buyingAnalyst ratingPrice upsideAI OutlookInsider track recordBreakout pressure

Plus AI summaries, the latest news for each stock, and an AI assistant you can ask questions about any of it.

Get started free with OTLK Insider Intel tracks insider activity at 3,154 companies right now. The Free plan includes full price charts and trade history, watchlists and email alerts.

Questions about OTLK insider trading

Who bought Outlook Therapeutics, Inc. (OTLK) stock recently?

Insiders who bought Outlook Therapeutics, Inc. stock on the open market in the last 12 months: Ghiath M. Sukhtian ($7.5M), KURT J HILZINGER ($177K), Faisal Ghiath Sukhtian ($150K), Yezan Munther Haddadin ($39K). The most recent purchase was reported on Aug 12, 2026.

Are insiders buying or selling OTLK?

Over the last 12 months insiders were net buyers of OTLK on discretionary trades: $7.9M bought against $0 sold (scheduled and tax-related sales excluded).

What is a sell-to-cover or 10b5-1 sale?

A 10b5-1 sale is scheduled in advance under a pre-arranged plan, and a sell-to-cover sale is made to pay tax on vesting shares. Neither is a fresh decision to sell, so they say less about an insider's view than a discretionary sale.

Where does this data come from?

Officers, directors and large shareholders report their trades to the SEC on Form 4. This page lists the open-market purchases and sales by individual insiders from those public filings; funds and other institutions are not shown.

Other stocks with recent insider buying

Ready to see OTLK in full?

Create a free account and open its chart, score and alerts.

Create your free account

How to read this page

Officers, directors and large shareholders must report their trades in company shares to the SEC on Form 4. This page lists open-market purchases and sales by individual insiders: trades made on the stock exchange at the going price. Funds and other institutions are not shown here.

Information from SEC EDGAR Form 4 filings, shown for general information only. It is not financial advice and does not recommend buying or selling any security. Trades are shown by transaction date and may be reported up to two business days later.